chr15-48470756-T-A
Variant summary
Our verdict is Pathogenic. Variant got 11 ACMG points: 11P and 0B. PM1PM2PM5PP2PP3_Strong
The NM_000138.5(FBN1):c.4337A>T(p.Asp1446Val) variant causes a missense, splice region change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predict no significant impact on normal splicing. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. D1446G) has been classified as Uncertain significance.
Frequency
Consequence
NM_000138.5 missense, splice_region
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 11 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
FBN1 | NM_000138.5 | c.4337A>T | p.Asp1446Val | missense_variant, splice_region_variant | 36/66 | ENST00000316623.10 | |
FBN1 | NM_001406716.1 | c.4337A>T | p.Asp1446Val | missense_variant, splice_region_variant | 35/65 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
FBN1 | ENST00000316623.10 | c.4337A>T | p.Asp1446Val | missense_variant, splice_region_variant | 36/66 | 1 | NM_000138.5 | P1 |
Frequencies
GnomAD3 genomes Cov.: 31
GnomAD4 exome Cov.: 32
GnomAD4 genome Cov.: 31
ClinVar
Submissions by phenotype
Familial thoracic aortic aneurysm and aortic dissection Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Dec 21, 2020 | The p.D1446V variant (also known as c.4337A>T), located in coding exon 35 of the FBN1 gene, results from a A to T substitution at nucleotide position 4337. This variant impacts the first base pair of coding exon 35. The aspartic acid at codon 1446 is replaced by valine, an amino acid with highly dissimilar properties. This variant was reported in a suspected Marfan case; however, no related clinical findings were described, and family history was the only indication provided (Baudhuin LM et al. J Hum Genet, 2015 May;60:241-52). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
Uncertain significance, criteria provided, single submitter | clinical testing | CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario | Nov 21, 2016 | - - |
Marfan syndrome Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Human Genome Sequencing Center Clinical Lab, Baylor College of Medicine | Feb 04, 2020 | The c.4337A>T (p.Asp1446Val) variant in the FBN1 gene has been reported in an individual with suspected Marfan syndrome (MFS) (PMID: 25652356). Missense variants at the same amino residue (Asp1446Gly, Asp1446Asn) have also been reported in patients with MFS (PMID: 25652356, 12938084). This variant is absent from general population databases. It is located at the first nucleotide of exon 36 of the FBN1 coding sequence and may affect splicing of the FBN1 transcript. The p.Asp1446Val change is located in the EGF-like domain of the FBN1 protein. Multiple lines of in silico algorithms have predicted this change to be deleterious. This variant was identified in an individual with a personal and family history suggestive of an autosomal dominant aortopathy syndrome. Therefore, this c.4337A>T (p.Asp1446Val) in the FBN1 gene is classified as likely pathogenic. - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Nov 03, 2014 | proposed classification - variant undergoing re-assessment, contact laboratory - |
Marfan syndrome;C4707243:Familial thoracic aortic aneurysm and aortic dissection Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | May 19, 2023 | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. This variant disrupts the p.Asp1446 amino acid residue in FBN1. Other variant(s) that disrupt this residue have been observed in individuals with FBN1-related conditions (PMID: 25907466, 33824467; Invitae), which suggests that this may be a clinically significant amino acid residue. An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. ClinVar contains an entry for this variant (Variation ID: 42358). This missense change has been observed in individual(s) with Marfan syndrome (PMID: 25652356). This variant is not present in population databases (gnomAD no frequency). This sequence change replaces aspartic acid, which is acidic and polar, with valine, which is neutral and non-polar, at codon 1446 of the FBN1 protein (p.Asp1446Val). - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at